Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02537691 · ClinicalTrials.gov registry record · Phase 4
Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers
A Phase 4 study of Asthma, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 4
- Development phase
- 483
- Enrollment target
- 20
- Study locations
NCT02537691 is a Phase 4 study of Asthma that has completed, run by Hoffmann-La Roche. The registered enrollment target is 483 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT02537691, a Phase 4 study of Asthma, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 483 participants
- Enrollment target
- 20
- Study locations
Study Summary
Prospective, single-arm, longitudinal, international, multicenter study in a real-world cohort of adult severe asthma participants being conducted to assess the relationships between asthma biomarkers and asthma-related health-outcomes for a period of 52 weeks.
Conditions Studied
Interventions
- DRUG Theophylline
- DRUG FP
- DRUG LABA
- DRUG LTRA
- DRUG LAMA
Study Locations (20)
New York
- Island Medical Research Pc - Commack
- Winthrop University Hospital - Mineola
- Laura and ISAAC Perlmutter Cancer Center at NYU Langone. - New York
- Montefiore Medical Center - The Bronx
California
- Southern California Research Center - Mission Viejo
- Capital Allergy Resp Dis Ctr - Sacramento
- Allergy Assoc Medical Group - San Diego
Florida
- AAADRS; Clinical Research Center - Coral Gables
- Volunteer Medical Research - Port Charlotte
- University of South Florida - Tampa
Pennsylvania
- Allergy-Asthma Specialists PC - Blue Bell
- Penn State Milton S. Hershey Medical Center - Hershey
- Allergy & Clinical Immun Assoc - Pittsburgh
Connecticut
- Yale New Haven Hospital - New Haven
- Waterbury Pulmonary Associates - Waterbury
Alabama
- Clinical Research Center of Alabama, LLC - Birmingham
Georgia
- Georgia Pollens Clinical Research Centers - Albany
Nebraska
- Asthma & Allergy Center, P.C. - Papillion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 483 participants |
| Start Date | 2015-08-28 |
| Est. Completion | 2017-07-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02537691
The ClinicalTrials.gov registry entry for NCT02537691 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 483 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (69% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 5 interventions - of which Theophylline is the first listed.
NCT02537691 reports 20 study locations spanning 10 distinct geographic areas - top geographies include New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02537691 about?
NCT02537691 is a clinical study titled "Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers". Prospective, single-arm, longitudinal, international, multicenter study in a real-world cohort of adult severe asthma participants being conducted to assess the relationships between asthma biomarkers and asthma-related health-outcomes for a period of 52 weeks.
What is the current status of trial NCT02537691?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 483 participants. The study started on 2015-08-28. Estimated completion is 2017-07-10.
What conditions does trial NCT02537691 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT02537691?
The interventions under investigation include: Theophylline (DRUG), FP (DRUG), LABA (DRUG), LTRA (DRUG), LAMA (DRUG).
Who is sponsoring clinical trial NCT02537691?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02537691 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.